{"id":"W2032810181","doi":"10.1016/j.bbmt.2009.11.021","title":"Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia","year":2009,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; Health Resources and Services Administration; Association of Medical Microbiology and Infectious Disease Canada; Society for Healthcare Epidemiology of America; Hospira; Infectious Diseases Society of America; CellGenix; Medical College of Wisconsin; Blue Cross and Blue Shield Association; American Society for Blood and Marrow Transplantation; Kiadis Pharma; Therakos; Centers for Disease Control and Prevention; Celgene; Osiris Therapeutics; WellPoint; Teva Pharmaceutical Industries; Oncology Nursing Society; Aetna; National Marrow Donor Program; AABB; U.S. Department of Health and Human Services; Astellas Pharma US; Amgen; U.S. Department of Defense; National Heart, Lung, and Blood Institute; Sysmex Corporation","keywords":"Medicine; Prolymphocytic leukemia; Internal medicine; Cumulative incidence; Confidence interval; Oncology; Population; Incidence (geometry); Hematopoietic cell; Leukemia; Transplantation; Surgery; Haematopoiesis; Stem cell; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002986043,0.0001479685,0.0002583294,0.0005366913,0.0003252811,0.0002415274,0.0001255484,0.0001489718,0.001911634],"category_scores_gemma":[0.0008270186,0.00006789354,0.0002309687,0.0005271434,0.0002136458,0.0001828505,0.000253576,0.0002684995,0.0004290812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001963544,"about_ca_system_score_gemma":0.0003766343,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003300055,"about_ca_topic_score_gemma":0.0005394819,"domain_scores_codex":[0.9998115,0.00005044935,0.00002476827,0.00002540309,0.00003846188,0.00004944679],"domain_scores_gemma":[0.9996362,0.0001079997,0.0001283304,0.00003196198,0.00001690063,0.00007858881],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006412574,0.0001213155,0.8965797,0.0001963451,0.000127391,0.01872111,0.0001516469,0.0002032729,0.003266682,0.0003014911,0.002322803,0.07736697],"study_design_scores_gemma":[0.0001792758,0.00108492,0.8706026,0.0001605356,0.0001626416,0.1142591,0.0002990173,0.0006520937,0.00271643,0.0007030576,0.009164395,0.00001590467],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889311,0.006091892,0.001036176,0.0002366817,0.00005273649,0.00006524171,0.0004652428,0.00003489171,0.003085974],"genre_scores_gemma":[0.9969136,0.001864785,0.0003280451,0.0001638221,0.00006559914,0.00001750493,0.0003999538,0.00000562735,0.0002409664],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001911634,"threshold_uncertainty_score":0.006395102,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0131323330492819,"score_gpt":0.2717403369524214,"score_spread":0.2586080039031395,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}